American Academy of Neurology (AAN) 2025 Annual Meeting
San Diego, California, US 05 April 2025 - 09 April 2025
AXS-05 delays relapse of Alzheimer's disease agitation
Treatment with AXS-05 significantly delayed the time to relapse of agitation in patients with Alzheimer’s disease (AD) compared with placebo, according to the phase III ACCORD-2 trial presented at AAN 2025.
Transnasal cooling a promising drug-free approach to tackling acute migraine attacks
An investigational neuromodulation device that delivers a controlled flow of dry, room-temperature air through the nasal passage helps relieve migraine pain, as shown in a study.
Tolebrutinib reduces disability accumulation in relapsing MS
Treatment with tolebrutinib results in a clear reduction in disability accumulation in patients with relapsing multiple sclerosis (MS) compared with teriflunomide despite no difference in relapses, according to the findings of the GEMINI 1 and 2 trials presented at AAN 2025.
X-TOLE OLE interim analysis shows long-term efficacy of novel agent for focal epilepsy
Interim data from the ongoing 7-year open-label extension (OLE) of the phase IIb X-TOLE study reflect the long-term efficacy and safety of azetukalner, an investigational, potent Kv7 potassium channel opener, for the treatment of adults with focal epilepsy.
